semaglutide .25 Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 mg daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) high blood pressure semaglutide .25 mg For patients

The medication itself is identical

Make sure to use it exactly as directed, and dont use more or less than prescribed without first consulting your doctor

Other payers who dropped GLP-1 coverage for weight loss this year include Harvard Pilgrim Health Care, Blue Cross Blue Shield of Michigan, and North Carolinas Medicaid program

Managing Side Effects: What to Expect During Dose Escalation Understanding cagrilintide side effects helps professionals guide clients through the escalation process and distinguish normal adaptation responses from concerning adverse events

In summary, the reasons a GP surgery may refuse an early B12 injection are often rooted in a strict interpretation of established, but imperfect, guidelines, a misunderstanding of the actual science of B12 storage and metabolism, and a desire to maintain administrative consistency